Physician profile
Patrick Duncan
NPI 1326577172
$9,440.87
in general payments reported to CMS, 2019-2025
30 companies · $7,043 in 2025
The $7,043 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $736 · 2024: $1,662 · 2025: $7,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238 · Education: $4,000 · Travel and Lodging: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.60 |
| Education | $4,000.00 |
| Travel and Lodging | $1,203.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,370.65 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $901.88 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $813.80 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.93 | 2023-2025 | Ofev, Spiriva Respimat, Jascayd |
| Insmed, INC. | $256.84 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $209.27 | 2024-2025 | Dupixent |
| Philips North America LLC | $192.01 | 2024-2025 | (8874) Incourage, Encore, Vest Therapy Und |
| Genzyme Corporation | $157.69 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $142.70 | 2024-2025 | Winrevair, Keytruda |
| Amgen INC. | $139.72 | 2023-2025 | Tezspire, Tavneos |
| Pulmonx Corporation | $137.74 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Tactile Systems Technology INC | $102.31 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Baxter Healthcare | $86.08 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Stryker Corporation | $82.60 | 2025 | Flowtriever |
| United Therapeutics Corporation | $78.41 | 2024-2025 | Tyvaso, Tyvaso |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $66.68 | 2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $47.67 | 2023-2024 | Glassia |
| Mylan Specialty L.P. | $41.53 | 2024 | Yupelri |
| Harmony Biosciences LLC | $40.21 | 2025 | |
| Axsome Therapeutics, INC. | $40.13 | 2023-2024 | Sunosi |
| Viatris Specialty LLC | $38.20 | 2025 | Yupelri |
| Electromed, INC. | $33.25 | 2024 | Smartvest |
| 3b Medical, INC. | $31.71 | 2024 | Luna |
| Ani Pharmaceuticals, INC. | $31.66 | 2025 | Purified Cortrophin Gel |
| Fisher & Paykel Healthcare INC | $31.54 | 2025 | Fisher & Paykel Healthcare |
| Abbvie INC. | $24.55 | 2024 | |
| Grifols USA, LLC | $21.13 | 2024 | Prolastin-C Liquid |
| Ambu INC. | $18.58 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $17.77 | 2023 | Vibativ |
| Azurity Pharmaceuticals, INC. | $17.63 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.